SG11202106347PA - Humanized anti-human-pd-1 antibody - Google Patents

Humanized anti-human-pd-1 antibody

Info

Publication number
SG11202106347PA
SG11202106347PA SG11202106347PA SG11202106347PA SG11202106347PA SG 11202106347P A SG11202106347P A SG 11202106347PA SG 11202106347P A SG11202106347P A SG 11202106347PA SG 11202106347P A SG11202106347P A SG 11202106347PA SG 11202106347P A SG11202106347P A SG 11202106347PA
Authority
SG
Singapore
Prior art keywords
antibody
human
humanized anti
humanized
Prior art date
Application number
SG11202106347PA
Other languages
English (en)
Inventor
Nicolas Poirier
Caroline Mary
Virginie Thepenier
Aurore Morello
Sabrina Pengam
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of SG11202106347PA publication Critical patent/SG11202106347PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202106347PA 2018-12-21 2019-12-17 Humanized anti-human-pd-1 antibody SG11202106347PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306801 2018-12-21
PCT/EP2019/085776 WO2020127366A1 (en) 2018-12-21 2019-12-17 Humanized anti-human-pd-1 antibody

Publications (1)

Publication Number Publication Date
SG11202106347PA true SG11202106347PA (en) 2021-07-29

Family

ID=65628503

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106347PA SG11202106347PA (en) 2018-12-21 2019-12-17 Humanized anti-human-pd-1 antibody

Country Status (19)

Country Link
US (2) US11352430B2 (ko)
EP (2) EP4257199A3 (ko)
JP (2) JP7043685B2 (ko)
KR (2) KR102371173B1 (ko)
CN (2) CN116063513A (ko)
AR (1) AR117465A1 (ko)
AU (1) AU2019406452B2 (ko)
BR (1) BR112021011982A2 (ko)
CA (1) CA3122526C (ko)
CL (1) CL2021001628A1 (ko)
CO (1) CO2021007956A2 (ko)
DK (1) DK3883966T3 (ko)
EA (1) EA202191751A1 (ko)
ES (1) ES2963700T3 (ko)
IL (2) IL296038A (ko)
MX (1) MX2021007290A (ko)
SG (1) SG11202106347PA (ko)
TW (1) TW202037608A (ko)
WO (2) WO2020127367A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3573600T1 (sl) 2017-01-25 2022-07-29 Ose Immunotherapeutics Postopek za proizvodnjo obstojne emulzije za dostavo peptida
EP3898677A1 (en) * 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
CA3201729A1 (en) 2020-12-17 2022-06-23 Nicolas Poirier Bifunctional anti-pd1/il-7 molecules
CN114763384B (zh) * 2021-01-14 2023-03-17 立凌生物制药(苏州)有限公司 靶向pd-1的单域抗体及其衍生物和用途
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2022214653A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
EP4353746A1 (en) * 2021-06-11 2024-04-17 Guangdong Fapon Biopharma Inc. Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
CN115521378B (zh) * 2021-07-23 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-l1抗体及其用途
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024077069A1 (en) * 2022-10-05 2024-04-11 Chulalongkorn University Monoclonal antibodies against human programmed cell death protein 1 (pd-1)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5275285A (en) 1992-12-30 1994-01-04 Clegg Industries Business card holder with sound generating microchip
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
MX2015015037A (es) * 2013-05-02 2016-07-08 Anaptysbio Inc Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
ES2843546T3 (es) 2014-04-18 2021-07-19 The Research Foundation Of The State Univ Of New York Anticuerpos humanizados anti-antígeno-TF
CN105330740B (zh) * 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
AU2016333517B2 (en) 2015-10-02 2023-09-07 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
BR112018014615A2 (pt) 2016-01-20 2018-12-11 The Scripps Research Institute composições de anticorpo para ror1 e métodos relacionados
CA3035932A1 (en) 2016-09-14 2018-03-22 Abbvie Biotherapeutics Inc. Anti-pd-1 antibodies and their uses
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
EP3609922A2 (en) 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
CA3076611A1 (en) 2017-09-23 2019-03-28 Memorial Sloan Kettering Cancer Center A33 antibody compositions and methods of using the same in radioimmunotherapy
AU2019232523A1 (en) 2018-03-05 2020-09-03 Etablissement Francais Du Sang Recombinant single chain immunoglobulins
EP3898677A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CA3122914A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/sirp.alpha. molecule
AU2019406453A1 (en) 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional molecule directed against human PD-1

Also Published As

Publication number Publication date
IL283812B2 (en) 2023-02-01
KR20220032646A (ko) 2022-03-15
ES2963700T3 (es) 2024-04-01
CN113557245A (zh) 2021-10-26
IL296038A (en) 2022-10-01
US20210355225A1 (en) 2021-11-18
CN116063513A (zh) 2023-05-05
EP3883966B1 (en) 2023-07-12
AU2019406452B2 (en) 2021-09-16
CA3122526A1 (en) 2020-06-25
WO2020127367A1 (en) 2020-06-25
WO2020127366A1 (en) 2020-06-25
AR117465A1 (es) 2021-08-11
EP4257199A2 (en) 2023-10-11
JP2022075824A (ja) 2022-05-18
CN113557245B (zh) 2022-10-25
CA3122526C (en) 2023-01-03
MX2021007290A (es) 2022-03-17
US11352430B2 (en) 2022-06-07
BR112021011982A2 (pt) 2021-09-14
IL283812B (en) 2022-10-01
KR102371173B1 (ko) 2022-03-04
EP4257199A3 (en) 2024-01-10
JP2022513528A (ja) 2022-02-08
EA202191751A1 (ru) 2021-10-12
US20220332826A1 (en) 2022-10-20
JP7404423B2 (ja) 2023-12-25
DK3883966T3 (da) 2023-10-16
IL283812A (en) 2021-07-29
CO2021007956A2 (es) 2021-10-29
CL2021001628A1 (es) 2022-01-07
KR20210097197A (ko) 2021-08-06
JP7043685B2 (ja) 2022-03-29
TW202037608A (zh) 2020-10-16
AU2019406452A1 (en) 2021-07-08
EP3883966A1 (en) 2021-09-29

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-SIRPalpha antibody
SG11202106214YA (en) Novel anti-ccr8 antibody
IL283812A (en) Humanized antibody against human pd–1
IL280780A (en) Anti-TIGIT antibodies
IL279352A (en) IL-11RA antibodies
IL280013A (en) Anti-IL36R antibodies
IL278010A (en) Antibodies to galectin 10
IL282756A (en) Humanized antibodies against SIRPα
IL262776A (en) Human anti-il-1r3 antibodies
IL277030A (en) Antibodies
GB202110263D0 (en) Anti-btla antibodies
ZA202101177B (en) Anti-btla antibody
ZA202004908B (en) Bispecific antibody
GB201811368D0 (en) Antibody
IL281594A (en) Antibodies against KLRG1
IL279823A (en) Antibodies cultured against PSMA
GB201817172D0 (en) Antibody
GB201806084D0 (en) Antibodies
GB201911211D0 (en) Monoclonal antibodies against ambra-1
GB201820006D0 (en) Humanised anti-IL17BR antibody
GB201813597D0 (en) Antibody
GB201809945D0 (en) Antibody
GB201819952D0 (en) Antibodies
GB201817312D0 (en) Antibodies
GB201817309D0 (en) Antibodies